Background Although percutaneous coronary intervention (PCI) had become widely
employed therapeutic procedure for coronary artery disease, stent restenosis limited the …

Background Although percutaneous coronary intervention (PCI) has become a widely used
therapeutic procedure for coronary artery disease, stent restenosis limits the benefits of this …

Cardiovascular disease is the leading cause of death worldwide, with coronary heart
disease as the major contributor to this related mortality. There is a growing trend in the …

Objective: To study therapeutic effect of Guanxintongluo (GXTL) capsule combined dual
antiplatelet drugs on prevention and treatment of in-stent restenosis after percutaneous …

Objective To further evaluate the effect of Xiongshao Capsule (XSC) on the restenosis (RS)
after percutaneous coronary intervention (PCI), based on previous clinical trials by which the …

Background Percutaneous coronary intervention (PCI) is a standard treatment for coronary
heart disease (CHD). Restenosis, defined as a 50% reduction in luminal diameter at six …

Objective: To analyze therapeutic effect of Mongolian medicine Guanxinshutong (MM)
capsule on restenosis af—ter stenting in patients with acute myocardial infarction (AMI) …

Objective To evaluate the effect of Xiongshao capsule (XSC) in preventing clinical and
angiographic restenosis after coronary angioplasty or/and stenting. Methods Sixty-five …

Objective To assess the effectiveness and safety of tongxinluo capsule for coronary heart
disease. Methods Trials were located electronic searches of the Cochrane Library (Issue 4 …

Background: Chinese patent medicines (CMPs) have curative effectiveness in preventing
coronary restenosis. However, the relative efficacy between different CPMs has not been …